Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

drug developers have long hoped that antibodies that can mop it up in extracellular spaces could slow its neurodegenerative effects. Genentech and AC Immune’s semorinemab was the first anti-tau ...

FDA may also require multiple assays to evaluate where the anti-drug antibodies bind to. Because of the increased requirements that commence and are applicable to the early stages of development ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.

US FDA approves Roche’s companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with Ziihera: Tucson, Arizona Tuesday, November ...

THIRUVANANTHAPURAM: The global shortage of anti-clotting drugs, or anticoagulants, did not affect the medication of over ...

“The initiation of this Phase 1 trial with GIGA-2339 represents a milestone in our mission to develop the next generation of ...